Skip to content

Colorado’s first licensed cannabis R&D firm to study marijuana’s effect on Alzheimer’s disease

March 6, 2020 / Arfinn Med MD /

Colorado’s first licensed cannabis R&D firm to study marijuana’s effect on Alzheimer’s disease

A Denver-based company hopes to be the state’s first to study the effects of marijuana on Alzheimer’s disease, thanks to a newly available research and development license in the city.

MedPharm Holdings plans to apply for a Denver marijuana R&D license to test delta-9 tetrahydrocannabinol (THC), cannabidiol (CBD) and other cannabinoids’ effects on Alzheimer’s and dementia patients.

According to the Alzheimer’s Association, 5.8 million Americans have the disease, a degenerative brain disorder that affects a person’s memory and thinking skills. While there are drugs that help ease symptoms, they do not change the course of the disease.

Albert Gutierrez, CEO of MedPharm, sees Alzheimer’s as “one of the biggest things that’s plaguing our country now and in the future.” That’s why he’s excited about cannabis’ potential to treat it.

Read Full Article Here

Stories you may be interested in

Americans Are Googling CBD More Than Acupuncture, Meditation And Exercise, Study Finds

People are increasingly more interested in CBD—or cannabidiol—than other health trends such as acupuncture, apple cider vinegar, exercise and veganism, according to a new review. In fact, the non-intoxicating cannabis compound has risen in popularity so much that people Google it nearly as much as they do for yoga and e-cigarettes. In a paper published…
Read More →

Norfolk research company plans clinical trials using medical marijuana

Eighteen months after receiving a broad federal license for importing medical cannabis, a Norfolk research company is about to embark on a series of critical studies into a variety of medical and mental disorders, diseases and conditions. Sanyal Biotechnology is already considering proposals for research campuses and planning its first clinical trial for this summer.…
Read More →

New Features

As Arfinn Med has become the leading Electronic Medical Record (EMR) and practice management solution for medical cannabis clinics, we have continued to release new features to help improve clinical workflows and patient care. Our newest feature is a custom intake form builder to help gather pertinent patient information prior to appointments. INTAKE FORM BUILDER…
Read More →

More baby boomers use medical marijuana, but they want their doctors to get wise to the risks and benefits

Baby boomers’ marijuana use has edged upward in the past decade, but recent research suggests some still have a hard time getting a hold of the drug. Older adults want more education, more research and greater openness with their health-care providers about using medical marijuana, according to a qualitative study of older cannabis users and non-users in…
Read More →

Survey of oncologists finds knowledge gap on medical marijuana

As more states legalize medical marijuana, two key groups — researchers whose job is it to understand its benefits and drawbacks, and physicians charged with advising potential users — are struggling to catch up with policymakers. Ilana Braun, an assistant professor of psychiatry at Harvard Medical School and chief of the division of adult psychosocial…
Read More →

Updated Arfinn Med Scheduler

As your practice begins to grow, it’s important that your booking system is able to keep up.  That’s why Arfinn Med has just released, in its newest update, the multi-view scheduling and booking platform.  This allows you and/or your staff the ability to customize appointment types, hours of availability, display name, and confirmation emails for…
Read More →

Leave a Comment

You must be logged in to post a comment.